ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Приведен анализ различных данных по вопросам формировании иммунного ответа у больных COVID-19. Показано, что в целом иммунный ответ при COVID-19 развивается преимущественно по клеточному типу. Гуморальный иммунный ответ, связанный с продукцией вируснейтрализующих антител обеспечивает защиту от инфекции в дальнейшем. Интересной является установленная перекрестная реактивность сывороток крови больных COVID-19 и SARS. Рассмотрены вопросы популяционного иммунитета и длительности сохранения антител к SARS-Cov-2.
Бугоркова С. А. 2020. Некоторые аспекты формирования иммунного ответа у пациентов с COVID-19. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111717
1. Huang C., Wang Y., Li X, Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., L i H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020: www.thelancet.com Published online January 24, 2020 https://doi.org/10.1016/S0140-6736(20)30183-5.
2. National Health Commission of the People’s Republic of China. Update on the novel coronavirus pneumonia outbreak (Feb 16, 2020). Available at: http://www.nhc.gov.cn/xcs/yqtb/202002/18546da875d74445bb537ab014e7a1c6.shtml.
3. A public health emergency of international concern over the global outbreak of novel coronavirus declared by WHO. Available at: https://www.who.int/dg/speeches/detail/whodirector-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov).
4. Li G., Fan Y., Lai Y., Han T., Li Z., Zhou .P, Pan P., Wang W., Hu D. , Liu X., Zhang Q. , Wu J. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32 DOI: 10.1002/jmv.25685.
5. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9. DOI: 10.12932/AP-200220-0772.
6. Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Version 2. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. PMID: 32221306.
7. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651.
8. Vinh Q. Chau, Estefania Oliveros, Kiran Mahmood, Aditi Singhvi, Anuradha Lala Noah Moss, Umesh Gidwani, Donna M Mancini, Sean P Pinney, Aditya Parikh. The Imperfect Cytokine Storm: Severe COVID-19 With ARDS in Patient on Durable LVAD Support JACC Case Rep . 2020 Apr 8. doi: 10.1016/j.jaccas.2020.04.001.
9. Coperchini F., Chiovato L., Croce L., Magri F., Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003. Epub 2020 May 11. PMID: 32446778.
10. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr;87(4):281-286. doi: 10.1007/s12098-020-03263-6. Epub 2020 Mar 13. PMID: 32166607.
11. Bai Y., Yao L., Wei T., Tian F., Jin D.Y., Chen L., Wang M. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020 Feb 21;323(14):1406-7. doi: 10.1001/jama.2020.2565. Online ahead of print. PMID: 32083643.
12. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.S. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 Mar 12. pii: ciaa248. doi: 10.1093/cid/ciaa248.
13. Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., Uhl S., Hoagland D., Møller R., Jordan T. X., Oishi K., Panis M., Sachs D., Wang T.T., Schwartz R.E., Lim J.K., Albrecht R.A., tenOever B.R. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Journal pre-proof CellPress 2020.04.026. DOI: 10.1016/j.cell.2020.04.026.
14. Fung S.Y., Yuen K.S., Ye Z.W., Chan C.P., Jin D.Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect .2020; 9 (1): 558–570. doi: 10.1080/22221751.2020.1736644. eCollection 2020.
15. Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., J.M. Crawford J.M., Daßler-Plenker J., Guerci P., Huynh C., Knight J.S. ,o Loda M., Looney M.R., McAllister F., Rayes R., Renaud S., Rousseau S., Salvatore S., Schwartz R.E., Spicer J.D., Yost C.C., Weber A., Zuo Yu., Egeblad M. Targeting potential drivers of COVID-19: neutrophil extracellular traps, J. Exp. Med. 2020; 217 (6): e20200652. DOI: 10.1084/jem.20200652
16. Nathan C. Neutrophils and COVID-19: Nots, NETs, and knots. J Exp Med. 2020;Sep 7;217(9):e20201439. doi: 10.1084/jem.20201439.
17. Casillo G.M., Mansour A.A., Raucci F., Saviano A., Mascolo N., Iqbal A. J., Maione F. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome? Pharmacol. Res. (2020) 104791. https://doi.org/10.1016/j.phrs.2020.104791.
18. Yazdanpanah F., Hamblin M.R., Rezaei N. The immune system and COVID-19: Friend or foe? Life Sciences.2020; 256 (1): 117900.https://doi.org/10.1016/j.lfs.2020.117900.
19. Zhagn S. , Li D., Chen H., Zheng D., Zhou Y., Chen B., Shi W., Lin R. Dynamic Inflammatory Response in a Critically Ill COVID-19 Patient Treated With Corticosteroids. Case Reports. 2020; 25;49(2):220-226. DOI:10.3785/J.ISSN.1008-9292.2020.03.10.
20. Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX, Miao Q. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020 Jul;81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012. Epub 2020 Apr 18.
21. Moro-Garcia MA, Alonso-Arias R, Lopez-Larrea C. When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes. Front Immunol 2013; 4: 107. DOI:10.3389/fimmu.2013.00107.
22. Channappanavar R., Fett C., Zhao J., Meyerholz D.K., Perlman S. Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection . J Virol. 2014; 88: 11034-11044. doi: 10.1128/JVI.01505-14. Epub 2014 Jul 23.
23. Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y. L., Hafezi M., Chia A., Chng M., Lin M., Tan N., Linster M., Chia W.N., Chen M. I.-C., Wang L.-F., Ooi E. E., Kalimuddin S., Tambyah P. A., Low J. G.-H., Tan Y.-J., Bertoletti A.. Different pattern of pre-existing SARS-COV-2 specific T cell immunity in SARS-recovered and uninfected individuals.2020 bioRxiv.
24. Chandrashekar A., Liu J., Martinot A.J., McMahan K., Mercado N.B., Peter L., Tostanoski L.H., Yu J., Maliga Z., Nekorchuk M., Busman-Sahay K., Terry M., Wrijil L.M., Ducat S., Martinez D.R., Atyeo C., Fischinger S., Burke J.S., Slein M.D., Pessaint L., Van Ry A., Greenhouse J., Taylor T., Blade K., Cook A., Finneyfrock B., Brown R., Teow E., Velasco J., Zahn R., Wegmann F., Abbink P., Bondzie E.A., Dagotto G., Gebre M.S., He X., Jacob-Dolan C., Kordana N., Li Z., Lifton M.A., Mahrokhian S.H., Maxfield L.F., Nityanandam R., Nkolola J.P., Schmidt A.G., Miller A.D., Baric R.S., Alter G., Sorger P.K., Estes J.D., Andersen H., Lewis M.G., Barouch D.H. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020, May 20; eabc4776. doi: 10.1126/science.abc4776.
25. Xing Y., Mo P., Xiao Y., Zhao O., Zhang Y., Wang F. Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro Surveill. 2020;25(10). doi:10.2807/1560-7917.ES.2020.25.10.2000191.
26. Xiao A.T., Tong Y.X., Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. J Med Virol. Published online April 9, 2020. doi:10.1002/jmv.25855.
27. Kirkcaldy R.D., King B.A., Brooks J.T. COVID-19 and Postinfection Immunity Limited Evidence, Many Remaining Questions. JAMA. 2020;323(22):2245-2246. doi:10.1001/jama.2020.7869.
28. Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., Wullimann D.J., Kammann T., Emgård J., Parrot T., Folkesson E., Rooyackers O., Eriksson L.I., Sönnerborg A., Allander T., Albert J., Nielsen M., Klingström J., Gredmark-Russ S., Björkström N.K., Sandberg J.K., Price D. A., Ljunggren H.-G., Aleman S., Buggert M. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.29.174888.
29. Ni L., Ye F., Cheng M.-L., Feng Yu, Deng Y.-Q., Zhao H., Wei P., Ge J., Gou M., liLi X., Sun L., Cao T., Wang P., Zhou C., Zhang R., Liang P., Guo H., Wang X., Dong C. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020, 52 (16): 971-977. https://doi.org/10.1016/j.immuni.2020.04.023.
30. Muacevic A., Adler J.R., Manners Ch., Bautista E.L., Sidoti H., Lopez O.J. Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines. Cureus. 2020; 12(6): e8399. doi: 10.7759/cureus.8399.
31. Liu W., Fontanet A., Zhang P.H., Zhan L., Xin Z.T., Baril L., Tang F., Lv H., Cao W.-Ch. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792-795. doi: 10.1086/500469. Epub 2006 Feb 9.
32. Liu W.J., Zhao M., Liu K., Xu K., Wong G., Tan W., Gao G.F. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2017; 137:82-92. doi: 10.1016/j.antiviral.2016.11.006.
33. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang. C.-L., Chen H.-D., Chen J. , Luo Y. , Guo H. , Jiang R.-D., Liu M.-Q. , Chen Y., Shen X.-R. , Wang X., Zheng X.-Sh., Zhao K., Chen Q.-J. , Deng F., Liu L.-L., Yan B., Zhan F.-X., Wang Y.-Y., Xiao G.-F. , Shi Z.-L.A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
34. Zhao J., Yuan Q., Wang H., Liu W., Liao X., Su Y. Wang X., Yuan J. , Li T., Li J., Qian Sh., Hong C., Wang F. , Liu Y., Wang Zh., He Q. , Li Zh., He B., Zhang T., Fu Y., Ge Sh. , Liu L., Zhang J. , Xia N., Zhang Zh. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease. Clin Infect Dis. 2020 Mar 28;ciaa344. doi: 10.1093/cid/ciaa344.
35. Long Q.-X., Deng H.-J., Chen J., Hu J., Liu B.-Zh., Liao P., Lin Y., Yu L.-H., Mo Zh., Xu Y.-Y., Gong F., Wu G., Zhang X.-Z., Chen Y.-K., Li Zh.-J., Wang K., Zhang X.-L., Tian W.-G., Niu Ch.-Ch., Yang Q.-J., Xiang J.-L., Du H.-X., Liu H.-W., Lang Ch., Luo X.-H., Wu Sh.-B., Cui X.-P., Zhou Zh., Wang J., Xue Ch.-J., Li X.-F., Wang L., Tang X.-J., Zhang Y., Qiu J.-F., Liu X.-M., Li J.-J., Zhang D.-Ch., Zhang F., Cai X.-F., Wang D., Hu Y., Ren J.-H., Tang N., Liu P., Li Q., Huang A.-L.Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv. Preprint. March, 2020. doi: https://doi.org/10.1101/2020.03.18.20038018.
36. Xiao Sh.-Y., Wu Y., Liu H.. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring J Med Virol. 2020; 92: 464–467. DOI: 10.1002/jmv.25702.
37. Amanat F., Stadlbauer D., Strohmeier Sh., Nguyen T., Chromikova V., McMahon M., Jiang K., Asthagiri-Arunkumar G., Jurczyszak D., Polanco J., Bermudez-Gonzalez M., Kleiner G., Aydillo T., Miorin L., Fierer D., Amarilis L., Kojic E. M., Stoever J., Liu S.T.H., Cunningham-Rundles Ch., Felgner Ph.L., Caplivski D., Garcia-Sastre A., Cheng A., Kedzierska K., Vapalahti O., Savolainen-Kopra C.A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv. Preprint. March, 2020. doi: doi: 10.1038/s41591-020-0913-5.
38. Guo L. , Ren L. , Yang S., Xiao M., Chang D., Yang F., Dela Ch. S. Cruz , Wang Y., Wu Ch., Xiao Y., Zhang L., Han L., Dang Sh., Xu Y., Yang Q., Xu Sh., Zhu H., Xu Y., Jin Q., Sharma L., Wang L., Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Clin Infect Dis . 2020 Mar 21;ciaa310. doi: 10.1093/cid/ciaa310. Online ahead of print.
39. Haveri A., Smura T., Kuivanen S., Österlund P., Hepojoki J., Ikonen N., Pitkäpaasi M., Blomqvist S., Rönkkö E., Kantele A., Strandin T., Kallio-Kokko H., Mannonen L., Lappalainen M., Broas M., Jiang M., Siira L., Salminen M., Puumalainen T., Sane J., Melin M., Vapalahti O., Savolainen-Kopra C. Serological and Molecular Findings During SARS-CoV-2 Infection: The First Case Study in Finland, January to February 2020. Euro Surveill 2020 Mar; 25(11): 2000266. doi: 10.2807/1560-7917.ES.2020.25.11.2000266
40. Chen X, Zhou B, Li M, Liang X, Wang H, Yang G, Wang H., Le X. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189(7):1158-63. 10.1086/380397.
41. Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, Law K.I., Tang B.S.F., Hon T.Y.W., Chan C.S., Chan K.H., Ng J.S.C., Zheng B.J., Ng W.L., Lai R.W.M., Guan Y., Yuen K.Y. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. 10.1016/S0140-6736(03)13412-5.
42. COVID-19-EPIDEMIC : Immunity after SARS-CoV-2 infection– a rapid review. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/immunity-after-sars-cov-2-infection-1st-update-report-2020.pdf.
43. Wighton D., Chazan D. Germany will issue coronavirus antibody certificates to allow quarantined to re-enter society. Telegraph March 29, 2020. https://www.telegraph.co.uk/news/2020/03/29/ germany-will-issue-coronavirus-antibody-certificates-allow-quarantined/. Accessed April 17, 2020.
44. Developing a National Strategy for Serology (Antibody Testing) in the United States (Contributors from Johns Hopkins University) https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/200422-national-strategy-serology.pdf/.
45. Tuzman K.T. NCI takes lead on serological test validation as cancer center joins COVID-19 fight. BioCentury April 9, 2020. https://www.biocentury.com/article/304874. Accessed April 11, 2020.
46. Hopper L. USC-L.A. County antibody testing may reveal when it’s safe to go back to work. USC News April 10, 2020. https://news.usc.edu/168497/antibody-testing-covid-19-pandemic-usc-losangeles-county/. Accessed April 17, 2020. 21.
47. McLaughlin E., Blankstein A. Large-scale COVID-19 antibody testing study launched in California. NBC News April 12, 2020. https://www.nbcnews.com/health/health-news/los.
48. Brotons C., Serrano J., Fernandez D., Garcia-Ramos C., Ichazo B., Lemaire J., Montenegro P., Moral I., Perez-Wienese R., Pitarch M., Puig M., Vilella M. T., Sellares J. Seroprevalence against COVID-19 and follow-up of suspected cases in primary health care in Spain. medRxiv. Preprint. June 13,2020. doi: https://doi.org/10.1101/2020.06.13.20130575.
49. Xiao D.A.T., Gao D.C., Zhang D.S. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect 2020 Mar 21. doi:10.1016/j.jinf.2020.03.012.
50. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520. doi: 10.3389/fimmu.2014.00520
51. Liu T., Wu S., Tao H., Zeng G., Zhou F., Guo F., Wang X.. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan - implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2 doi: https://doi.org/10.1101/2020.06.13.20130252.
52. Bao L., Deng W., Gao H., Xiao C., Liu J., Xue J., et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. medRxiv. Preprint. March 13, 2020. doi: https://doi.org/10.1101/2020.03.13.990226.
53. Wu L.-P., Wang N.-C., Chang Y.-H., Tian X.-Y., Na D.-Y., Zhang L.-Y., Zheng L., Lan T., Wang L.-F., Liang G.-D. . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007; 13(10): 1562-1564. doi: 10.3201/eid1310.070576.
54. Guo X., Guo Z., Duan C., Сhen Z., Wang G., Lu Y., Lu Y., Li M., Lu J. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. medRxiv. Preprint. Februry 14, 2020 https://doi.org/10.1101/2020.02.12.20021386.
55. Kellam P., Barclay W. The dynamics of humoral immune responses following SARS- CoV-2 infection and the potential for reinfection. Journal of General Virology. 2020. May 20. DOI/10/11099/jgv.0.001439.
56. Wu F., Wang A., Liu M., Wang Q., Chen J., Xia Sh., Ling Y., Zhang Y., Xun J., Lu L., Jiang Sh., Lu H., Wen Yu., Huang J. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. Preprint. April 20, 2020. doi:10.1101/2020.03.30.20047365.
57. Müller M.A., Corman V.M., Jores J., Meyer B., Younan M., Liljander A., Bosch B.-J., Lattwein E., Hilali M., Musa B.E., Bornstein S., Drosten Ch.MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983-1997. Emerg Infect Dis 2014;20(12):2093-2095. doi: 10.3201/eid2012.141026.
